129-15-7Relevant articles and documents
Novel anthraquinone compounds inhibit colon cancer cell proliferation via the reactive oxygen species/JNK pathway
Chen, Tinggui,Feng, Liheng,Guan, Yingying,Guo, Fang,Li, Yuying,Liu, Yaoming,Ma, Kaiqing,Su, Qiang,Wang, Zhuanhua,Zhang, Liwei,Zhou, Yuzhi
supporting information, (2020/04/10)
A series of amide anthraquinone derivatives, an important component of some traditional Chinese medicines, were structurally modified and the resulting antitumor activities were evaluated. The compounds showed potent anti-proliferative activities against eight human cancer cell lines, with no noticeable cytotoxicity towards normal cells. Among the candidate compounds, 1-nitro-2-acyl anthraquinone-leucine (8a) showed the greatest inhibition of HCT116 cell activity with an IC50 of 17.80 μg/mL. In addition, a correlation model was established in a three-dimensional quantitative structure-activity relationship (3D-QSAR) study using Comparative Molecular Field Analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA). Moreover, compound 8a effectively killed tumor cells by reactive oxygen species (ROS)-JNK activation, causing an increase in ROS levels, JNK phosphorylation, and mitochondrial stress. Cytochrome c was then released into cytoplasm, which, in turn activated the cysteine protease pathway and ultimately induced tumor cell apoptosis, suggesting a potential use of this compound for colon cancer treatment.
OXIDATIVE NITRATION OF ANTRAQUINONE AND 2-METHYLANTHRAQUINONE
Ponomarev, V. A.,Esip, V. P.,Yakobi, V. A.
, p. 1682 - 1684 (2007/10/02)
-
